tiprankstipranks
Trending News
More News >

Venus Medtech Schedules Board Meeting to Review Annual Results

Story Highlights
Venus Medtech Schedules Board Meeting to Review Annual Results

Don’t Miss TipRanks’ Half-Year Sale

Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) just unveiled an update.

Venus Medtech (Hangzhou) Inc. has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation for a final dividend payment and address any other business matters, potentially impacting the company’s financial strategies and stakeholder interests.

More about Venus Medtech (Hangzhou), Inc. Class H

Venus Medtech (Hangzhou) Inc. is a company incorporated in the People’s Republic of China, focusing on the medical technology industry. The company specializes in developing and manufacturing medical devices, with a particular emphasis on innovative cardiovascular solutions.

YTD Price Performance: -69.57%

Average Trading Volume: 50,758,466

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$780.6M

For an in-depth examination of 2500 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1